Research Paper Volume 15, Issue 7 pp 2797—2811

Figure 2. Dex treatment protected OGD/R-exposed Neuro-2a cells through up-regulation of HOXA11-AS expression and increased cell survival. (A) Neuro-2a cells with or without OGD/R were pre-treated with 10 μM Dex. The expression of HOXA11-AS was determined by quantitative real-time PCR. (B, C) Knockdown (B) and over-expression (C) of HOXA11-AS by transfection of sh-HOXA11-AS and pcDNA3.1-HOXA11-AS, respectively, were verified by quantitative real-time PCR. (D–F) Neuro-2a cells were transfected with control empty vector or pcDNA3.1-HOXA11-AS vector, and were left untreated or received OGD/R. Relative expression of HOXA11-AS (D), cell proliferation (E) and apoptosis of cells (F) in the indicated groups were quantitated. (G–I) Neuro-2a cells transfected with control sh-RNA or sh-HOXA11-AS were left untreated or treated with 10 μM Dex. Cells were then subjected to OGD/R. Relative expression of HOXA11-AS (G), cell proliferation (H) and apoptosis of cells (I) in the indicated groups were quantitated. n = 3 for each group; ^*P < 0.05, compared between the indicated groups.